Upstream Bio (UPB) Expected to Release Earnings on Wednesday

Key Points

• Upstream Bio is expected to report Q3 2026 results before the market opens on November 4. Analysts forecast a loss of $0.7286 per share and revenue of approximately $0.52 million.
• The company’s previous quarter exceeded expectations, with an adjusted loss of $0.73 per share versus the $0.74 consensus estimate and revenue of $0.77 million compared with the $0.56 million forecast.
• UPB shares opened at $2.79, near their 12-month low of $2.68 and well below the 12-month high of $33.68. Analysts maintain a consensus “Hold” rating, with an average price target of $29.67.

Upstream Bio (NASDAQ:UPB - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.7286) per share and revenue of $0.52 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.01. The company had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. On average, analysts expect Upstream Bio to post ($2.84) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.

Upstream Bio Stock Performance

UPB opened at $2.79 on Wednesday. The firm has a market cap of $152.81 million, a P/E ratio of -0.96 and a beta of 1.38. The business has a 50 day moving average price of $5.16 and a 200 day moving average price of $9.90. Upstream Bio has a twelve month low of $2.68 and a twelve month high of $33.68.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. JPMorgan Chase & Co. increased their price target on Upstream Bio from $8.00 to $9.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Weiss Ratings upgraded shares of Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 17th. Wall Street Zen downgraded shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of Upstream Bio in a report on Wednesday, September 2nd. Finally, Truist Financial lowered their target price on shares of Upstream Bio to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $29.67.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company's research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.